Founding Organizations:

In this high-energy and insightful presentation, Dr. Janardhan delivers a comprehensive overview of the evolving landscape of Metabolic dysfunction-Associated Steatohepatitis (MASH), formerly known as NASH. As the prevalence of fatty liver disease continues to surge alongside rising rates of obesity and type 2 diabetes, MASH has become a significant global health concern. Developed in collaboration with the Chronic Liver Disease Foundation and the Global NASH Council, this session provides healthcare providers with practical, real-world strategies for identifying, staging, and managing patients at risk for advanced liver disease.

Viewers will learn how to apply the three-phase approach to MASH management—beginning with lifestyle modification, followed by pharmacologic therapy (including FDA-approved resmetirom), and finally referral to clinical trials when appropriate. The presentation outlines the power and utility of non-invasive testing (NITs) such as FIB-4, ELF, transient elastography (FibroScan), and MR elastography to assess liver fibrosis without the need for biopsy. It emphasizes the critical role of fibrosis as a predictor of liver-related mortality and how early identification can significantly impact patient outcomes.

Dr. Janardhan also dives deep into the metabolic underpinnings of MASH, connecting it to cardiometabolic risk factors including insulin resistance, dyslipidemia, and systemic inflammation. Viewers will explore evidence-based lifestyle interventions—from the Mediterranean diet and intermittent fasting to exercise thresholds, weight loss medications, and bariatric procedures—all tailored to support sustainable outcomes. The talk also highlights the importance of individualized care and the necessity of building multidisciplinary teams that integrate endocrinology, obesity medicine, nutrition, and hepatology.